StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Research analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued to investors on Friday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Down 3.7 %

Shares of NYSE ENZ opened at $0.68 on Friday. Enzo Biochem has a twelve month low of $0.68 and a twelve month high of $1.44. The business has a 50 day simple moving average of $0.93 and a 200-day simple moving average of $1.05.

Enzo Biochem (NYSE:ENZ) last released its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its stake in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem during the third quarter worth about $112,000. Geode Capital Management LLC increased its holdings in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares during the period. Finally, Renaissance Technologies LLC lifted its position in Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.